End-of-life health care utilization (EOLHCU) in patients with recurrent, metastatic head and neck squamous cell carcinoma (RMHNSCC) treated with immune checkpoint inhibitors (IO). This is an ASCO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback